Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 8-9, Août–Septembre 2006
Page(s) 751 - 754
Section M/S revues
DOI https://doi.org/10.1051/medsci/20062289751
Publié en ligne 15 août 2006
  1. Kovacs JA, Baseler M, Dewar RJ,et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection : a preliminary study. N Engl J Med 1995; 332 : 567–75.
  2. Kovacs JA, Vogel S, Albert JM, et al. Sustained increases in CD4 counts with intermittent interleukin-2 therapy in HIV-infected patients with greater than 200 CD4 cells/mm3 : results of a randomized, controlled trial. N Engl J Med 1996; 335 : 1350–6.
  3. Davey RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in HIV-1 infected persons. J Infect Dis 1997; 175 : 781–9.
  4. Levy Y, Capitant C, Houhou S, et al. For the ANRS 048 study group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection : a randomised controlled trial. Lancet 1999; 353 : 1923–9.
  5. Davey RT, Chaitt DJ, Albert JM, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179 : 849–58.
  6. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy : a randomized controlled trial. JAMA 2000; 284 : 183–9.
  7. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral treatment on immune restoration in HIV-1 infection : a randomized controlled trial. AIDS 2003; 17 : 343–51.
  8. Arduino RC, Nannini EC, Rodriguez-Barradas M, et al. CD4 cell response to 3 doses of subcutaneous interleukin 2 : meta-analysis of 3 vanguard studies. Clin Infect Dis 2004; 39 : 115–22.
  9. Gougeon ML, Rouzioux C, Liberman I, et al. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patient. AIDS 2001; 15 : 1729–31.
  10. Farel CE, Chaitt DG, Hahn BK, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103 : 3282–6.
  11. Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effect of intermittent interleukin-2 therapy in patients with HIV infection : characterization of a novel subset of CD4+/CD25+ T cells. Blood 2002; 100 : 2159–67.
  12. Sereti I, Anthony KB, Martinez-Wilson H, et al. IL-2-induced CD4+ T cell expansion in HIV-infected patients is associated with long term decreases in T-cell proliferation. Blood 2004; 104 : 775–80.
  13. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115 : 2139–48.
  14. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2 treated HIV-infected patients. J Clin Invest 2005; 115 : 1839–47.
  15. Weiss L, Donkova-Petrini V, Aouba A, Levy Y. CD4+CD25+ regulatory T cells are detectable in peripheral blood of HIV-infected patients treated with IL-2. Rio de Janeiro : 3rd IAS Conference, 2005 : We.Pe.16.5.B06 (abstract).
  16. Weiss, L, Donkova-Petrini, V, Caccavelli, L, et al. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 101 : 3249–56.
  17. Kinter A, Hennessey M, Bell A, et al. CD25+CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favourable clinical markers of disease status. J Exp Med 2004; 200 : 331–43.
  18. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9 : 540–7.
  19. Valdez H, Mitsuyasu R, Landay A, et al. Interleukin-2 induces increases in CD4+ lymphocyte numbers but does not enhance responses to immunization : results of A5046s. J Infect Dis 2003; 187 : 320–5.
  20. Levy Y, Gahery-Segard H, Durier C, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patient. AIDS 2005; 19 : 279–86.
  21. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161 : 1875–82.
  22. ESPRIT IL-2 trial (online) http://www.espritstudy.org.
  23. SILCAAT study design (online) http://www.silcaatstudy.org.
  24. Fry TJ, Mackall C. Interleukin-7 : from bench to clinic. Blood 2002; 99 : 3892–904.
  25. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients : relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999; 8 : 783–8.
  26. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion. Implications for T cell homeostasis. Nat Med 2001; 7 : 73–9.
  27. Smithgall MD, Wong JG, Critchett KE, Haffar OK. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1996; 156 : 2324–30.
  28. Steffens CM, Managlia EZ, Landay A, Al-Harthi L. Interleukin-7 treated naïve T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 2002; 99 : 3310–8.
  29. Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101 : 2294–9.
  30. Nugeyre MT, Monceaux V, Beq S, et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol 2003; 171 : 4447–53.
  31. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115 : 128–37.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.